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ABSTRACT 
 
Introduction:  
Management of tuberculosis (TB) is challenging in HIV/TB co-infected children. The World Health 
Organization (WHO) recommends nucleic acid amplification tests for TB diagnosis, a four-drug regimen 
including ethambutol during intensive phase of treatment (IP), and initiation of antiretroviral therapy 
(ART) within eight weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic 
modality, IP regimen, and ART status. 
Methods:  
We conducted a retrospective cohort study among HIV/TB co-infected children enrolled at International 
Epidemiology Databases to Evaluate AIDS treatment sites from 2012-2014. We modeled TB outcome 
using multivariable logistic regression including diagnostic modality, IP regimen, and ART status.  
Results:  
Among 386 HIV-infected children diagnosed with TB, 20% had microbiological confirmation of TB, and 
20% had unfavorable TB outcomes. During IP, 78% were treated with a four-drug regimen. Thirty-one 
percent were receiving ART at the time of TB diagnosis, and 32% were started on ART within eight weeks 
of TB diagnosis. Incidence of ART initiation within eight weeks of TB diagnosis was higher for those with 
favorable TB outcomes (64%) compared to those with unfavorable outcomes (40%) (p=0.04). Neither 
diagnostic modality (OR 1.77; 95%CI 0.86-3.65) nor IP regimen (OR 0.88; 95%CI 0.43-1.80) were 
associated with TB outcome.  
Discussion:  
In this multinational study of HIV/TB co-infected children, many were not managed per WHO guidelines. 
Children with favorable TB outcomes initiated ART sooner than children with unfavorable outcomes. 
These findings highlight the importance of early ART for children with HIV/TB co-infection, and reinforce 
the need for implementation research to improve pediatric TB management. 
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INTRODUCTION 
 
Tuberculosis (TB) remains a major cause of childhood morbidity and mortality in low- and middle-
income countries (LMIC). Human Immunodeficiency Virus (HIV) has amplified the TB epidemic, as 
evidenced by the disproportionate impact of TB in areas with high HIV prevalence, especially Sub-
Saharan Africa and Southeast Asia.
1-3
 Among children in 2014, there were an estimated 1 million 
incident TB cases, 140,000 deaths attributable to TB, and approximately 40% of TB deaths were among 
those with HIV/TB co-infection.
1
  
 
The World Health Organization (WHO) defines TB treatment success as documented cure or completion 
of anti-TB therapy (ATT); unsuccessful TB treatment outcomes include death, treatment failure, default 
from care/loss to follow-up (LTFU), or unknown outcome.
4
 Compared to HIV-negative individuals, 
HIV/TB co-infected individuals are less likely to have successful TB treatment outcomes.
1
  
 
Despite limited data on pediatric TB outcomes,
3,5-11
 WHO has developed guidelines for the management 
of HIV/TB co-infected children in LMIC.
6
 These recommendations include: nucleic acid amplification 
testing (NAAT) as the initial TB diagnostic test for children with HIV-associated TB;
6,12
 using a four-drug 
regimen including ethambutol during the intensive phase (IP; first two months) of ATT in TB endemic 
areas with background isoniazid resistance;
6,13,14
 antiretroviral therapy (ART) initiation within eight 
weeks of starting ATT, for ART naïve patients;
6
 and, for those already receiving ART at the time of TB 
diagnosis, to optimize ART regimens to avoid drug-drug interactions.
6,15
  
 
However, it is unclear to what extent these recommendations have been implemented in pediatric ART 
programs in LMIC. Limited availability of diagnostics, challenges with obtaining sputum, and 
paucibacillary disease which may be more pronounced in HIV/TB co-infected children may result in 
many children being diagnosed with TB on clinical criteria alone (without microbiologic confirmation 
with NAAT, acid-fast bacilli [AFB] culture, and/or AFB smear).
12,16-19
 Despite studies demonstrating low 
risk for ethambutol associated ocular toxicity,
13,14
 some practitioners still opt to prescribe a three-drug IP 
regimen lacking ethambutol for preverbal children. Similarly, some providers delay ART initiation 
beyond the recommended eight weeks after ATT initiation to avoid immune reconstitution 
inflammatory syndrome (IRIS), which is uncommon among children.
20,21
 And, in the setting of 
medication stock-outs,
22-24
 limited availability of fixed-dose combination drug options,
25
 and adherence 
challenges with pediatric formulations of ART and ATT medications,
26,27
 optimizing regimens for 
potential ART-ATT interactions can be challenging.
15,28
 
 
We set out to investigate these issues using data collected from sites participating in the International 
Epidemiology Databases to Evaluate AIDS (IeDEA).
29
 The objectives of this research are to: (1) provide 
recent patient-level data on the care and treatment of HIV/TB co-infected children; (2) assess whether 
TB treatment outcomes differ based on TB diagnostic modality, IP regimen, or ART status; and, (3) 
describe ART regimens and modifications made to ART regimens in the setting of ATT. 
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METHODS 
 
Study Design and Population 
 
We conducted a retrospective cohort study among HIV/TB co-infected children aged 0 through 15 years. 
Children were enrolled from 14 participating ART programs in 11 LMIC, representing five IeDEA regions 
(Figure 1).
29
 Previously treated TB cases were included (n=8), so a patient could contribute more than 
one TB episode.  
 
Data Collection 
 
Local TB registries were utilized to identify TB cases diagnosed at participating IeDEA sites from January 
2012 through December 2014. Patient demographics, laboratory data, TB treatment regimens, and TB 
outcomes were collected retrospectively using a standardized electronic case report form (CRF) 
developed in Research Electronic Data Capture (REDCap).
30
 The CRF was piloted prior to 
implementation, and was made available in English and French. The French version was translated by an 
IeDEA co-investigator who is a native French speaker and engaged in HIV/TB research. Local IeDEA site 
investigators completed CRFs for TB cases following electronic and/or hard copy medical record review. 
Data entry took place from January 2012 through January 2016. Information on ART initiation dates and 
ART regimens were obtained from IeDEA regional HIV care and treatment data repositories for all 
patients with a completed CRF. Throughout the period of data collection, routine audits were made to 
ensure data quality. After database closure the data was further verified, and any suspected data quality 
issues were referred back to local sites for investigation, clarification, and revision when necessary.  
 
Definitions  
 
Any diagnosis of new or previously treated active TB while enrolled at one of the participating ART sites 
was considered a unique TB episode. Utilizing WHO definitions,
4
 we grouped TB treatment outcomes 
into favorable and unfavorable categories. Documented cure or completion of ATT were considered 
favorable TB treatment outcomes. Death, treatment failure, default from care/LTFU, or unknown 
outcome were considered unfavorable TB treatment outcomes – the primary outcome of interest. 
Children still on ATT at database closure or who transferred care to another facility were excluded from 
the analysis of TB treatment outcomes.  
 
Our primary exposure variables of interest were diagnostic modality, IP regimen, and ART status. A 
microbiologic diagnosis was considered to be any diagnosis of TB that was confirmed by at least one 
laboratory test (AFB smear, mycobacterial culture, or NAAT). A clinical diagnosis was any TB diagnosis 
that was made without a positive laboratory test result; children with clinical diagnoses could have had 
negative diagnostic test result(s) or no diagnostic testing performed. All TB diagnoses included a 
decision to start ATT.  
 
IP regimen was dichotomized by those who received the recommended four-drug IP regimen (Isoniazid 
[H], rifampin [R], pyrazinamide [Z], ethambutol [E]; HRZE) and those who received a three-drug IP 
regimen lacking ethambutol (HRZ). 
 
ART status at the time of TB diagnosis was categorized as ART naïve or previously on ART. Among those 
who were ART naïve at the time of TB diagnosis, we also calculated time to ART initiation from TB 
diagnosis by subtracting the date of ATT initiation from ART initiation date. ART regimens were classified 
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into the following categories based on WHO recommendations:
31
 three nucleoside reverse transcriptase 
inhibitors (NRTI); two NRTI plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI); two NRTI plus 
a boosted protease inhibitor (PI), and non-standard (“other”) regimens. ART regimen modifications 
made within eight weeks of TB diagnosis date were included as ART modifications made in the setting of 
ATT initiation.  
 
Key covariates at TB diagnosis included age, sex, weight, CD4 count (and CD4 percentage), and IeDEA 
region (Asia-Pacific, Central Africa, Eastern Africa, Southern Africa, and Western Africa; Figure 1). The 
date of TB diagnosis was defined as the date of the first positive microbiologic test or clinical diagnosis 
of TB. CD4 count at TB diagnosis was defined as the first available value 180 days before or up to 30 days 
after the date of TB diagnosis. HIV viral loads were not routinely collected or reported at some 
treatment sites participating in this study. Weight-for-age Z-scores (WAZ) at TB diagnosis were 
calculated as a marker of nutritional status using United States Centers for Disease Control (CDC) 
standards.
32
 WHO standards are more commonly used to calculate WAZ in LMIC since the reference 
population from which they are derived is more diverse than the CDC reference population; however, 
the WHO standard only extends through 10 years of age, while the CDC standard extends through 18 
years. Therefore, to maintain a consistent metric for our population of children 0-15 years of age, we 
elected to use the CDC standard. Regardless of the reference population, WAZ is a relative measure and 
lower WAZ scores indicate a greater degree of undernutrition. 
  
Statistical Analyses 
 
Descriptive statistics were used to summarize patient characteristics, TB diagnostics, TB treatment, TB 
outcomes, ART status, ART regimens, and modifications made to ART regimens in the setting of TB 
diagnosis and treatment. For continuous variables, median and interquartile ranges (IQR) are reported. 
Frequency and percentages are reported for categorical variables.    
 
Multivariable logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval 
(CI) of unfavorable TB treatment outcome associated with mode of diagnosis, IP regimen, and ART 
status while adjusting for age, sex, WAZ, CD4 count/percentage, and IeDEA region. Multiple imputation 
was used to account for missing data. Continuous variables were modeled as linear terms as there was 
no evidence for non-linearity. Acknowledging that there may be important differences between 
diagnostic and treatment strategies for younger children, an a priori decision was made to perform 
secondary regression analyses for the sub-groups of children younger than five years of age and children 
aged 5-15 years. The same covariates were included in main and secondary models, except CD4 
percentage was used instead of CD4 count for those younger than five years. Sensitivity analyses 
excluding the small number of previously treated TB cases were also performed.  
 
Among those who were ART naïve at TB diagnosis, we compared ART initiation across TB outcomes. 
Anticipating that LTFU during the eight weeks after TB diagnosis might make it difficult to investigate the 
effect of ART initiation during the first eight weeks, we plotted the cumulative incidence of ART initiation 
among groups with unfavorable and favorable TB treatment outcome restricted to those that were alive 
and in care at eight weeks after TB diagnosis, and tested the association using a log-rank test.  
 
R version 3.2.5 (www.r-project.org) was used for all analysis and code is available online 
(http://biostat.mc.vanderbilt.edu/ArchivedAnalyses).  
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Ethical Considerations 
 
Local institutional review board or ethics committee approval was obtained from all local study sites as 
well as Vanderbilt University. Procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2013.  
 
 
RESULTS  
 
Patient Characteristics 
 
There were 400 children under the age of 16 diagnosed with TB and with a TB CRF entered into REDCap 
during the study period. Fourteen (3.5%) were excluded; one was still on ATT and 13 had transferred to 
another facility. Among 386 children included, the median age was 5.7 years (IQR 2.0-9.5) and 47% were 
female. Median WAZ was -2.69 (IQR -3.82, -1.48; 17% missing data). Median CD4 count among those ≥ 5 
years was 144 cells/mm
3
 (IQR 28-403 cells/mm
3
; 14% missing data). Median CD4 percentage among 
those < 5 years was 16% (IQR 8-23%; 34% missing data) (Table 1). The children were recruited from 14 
ART programs in 11 LMIC (Burundi, Côte d’Ivoire, Ghana, Indonesia, Kenya, République Démocratique 
du Congo, Rwanda, South Africa, Tanzania, Uganda, and Vietnam), each contributing between one and 
91 children (Figure 1). 
 
TB Diagnosis 
 
Among the 386 HIV/TB co-infected children, 79 (20%) had microbiological confirmation of TB, while 307 
(80%) were diagnosed clinically. Of the 79 with at least one positive diagnostic test, 36 (46%) had a 
positive AFB smear, 33 (42%) had a positive mycobacterial culture, and 48 (61%) had a positive NAAT 
(Table 2). In terms of diagnostic yield, 59% (229/386) of cases were tested with AFB smear, but only 16% 
(36/229) of those tests were positive; 32% (123/386) of cases were tested with AFB culture, and 27% 
(33/123) of those tests were positive; while only 22% (84/386) of cases were tested with NAAT, but 57% 
(48/84) of those tests were positive. Of the 307 cases diagnosed clinically, 155 (50%) had at least one 
test but no positive result, and 152 (50%) did not have a laboratory diagnostic test performed. Overall, 
287 (74%) of cases were classified as PTB, 73 (19%) were classified as EPTB, and 25 (6%) were classified 
as having both PTB and EPTB. Among those with EPTB, the most common sites were abdominal (9%) and 
lymphatic (7%) (Table 2).  
 
Only three cases (<1%) were found to have INH or rifampin resistance, one of which was in the Asia-
Pacific region, and the other two were in the Southern Africa region. These regions were also the only 
two regions that were routinely utilizing NAAT for TB diagnosis, and were the primary regions where 
gastric aspirates and induced sputum were utilized to obtain diagnostic specimens.  
 
TB Treatment Regimens 
 
As for IP regimens, 84 (22%) cases were treated with a non-standard 3-drug regimen lacking 
ethambutol, while 302 (78%) were treated with a 4-drug regimen including ethambutol (Table 2). The 
practice of omitting ethambutol was common in Eastern Africa, Central Africa, and Western Africa 
regions where such IP regimens were prescribed for 47%, 36%, and 27% of cases, respectively. IP 
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regimens lacking ethambutol were prescribed to children less than five years of age in 32% of cases, and 
to children aged 5-15 years in 15% of cases.      
 
ART Status 
 
One hundred and nineteen (31%) of 386 HIV/TB co-infected children were receiving ART prior to their TB 
diagnosis. Of the 267 (69%) not on ART at the time of starting ATT, 124 (46%) initiated ART within eight 
weeks of starting ATT, and 53 (20%) more initiated ART more than eight weeks after starting ATT. Fifty 
(13%) of the HIV/TB co-infected children did not initiate ART by the end of the study period. ART status 
data was missing for 40 (10%) children (Table 2). 
 
Many ART regimens were modified when starting ATT. Among the 114 patients active on ART eight 
weeks prior to TB diagnosis, 64% of the ART regimens were comprised of two NRTI plus a NNRTI (32% 
efavirenz, 32% nevirapine), 16% were comprised of two NRTI plus a boosted PI, 2% were comprised of 
three NRTI, and 18% were non-standard regimens. The majority of children receiving an efavirenz-based 
(97%), boosted PI-based (94%), or three NRTI (100%) regimen remained on the same ART regimen after 
TB diagnosis. Sixty percent of children on a nevirapine-based regimen remained on the same regimen 
after TB diagnosis, 32% switched to an efavirenz-based regimen, 3% switched to a boosted PI-based 
regimen, and 3% switched to three NRTI. Two percent experienced an interruption in ART after TB 
diagnosis. Children initiating ART within eight weeks of TB diagnosis were started on the following 
regimens: two NRTI plus a NNRTI (78%; 66% efavirenz, 12% nevirapine), two NRTI plus a boosted PI (8%), 
three NRTI (2%), and other non-standard regimens (12%) (supplemental figure accessible at:  
http://biostat.mc.vanderbilt.edu/MeridithBlevins/pediatric-tb-hiv-sunburst.html). Dose adjustments for 
ART and/or ATT also may have occurred, but dosing data was not captured. 
   
TB Treatment Outcomes 
 
Among the 386 HIV/TB co-infected children, 78 (20%) had unfavorable TB treatment outcomes and 308 
(80%) had favorable outcomes. Among the 78 with unfavorable outcomes, 30 (38%) died, 1 (1%) had 
treatment failure, 33 (42%) were LTFU, and 14 (18%) had unknown outcomes. The proportion of 
unfavorable outcomes attributable to LTFU was 1% (1/84) in the Asia-Pacific region, 7% (4/60) in the 
Central Africa region, 3% (3/94) in the Eastern Africa region, 9% (8/88) in the Southern Africa region, and 
28% (17/60) in the Western Africa region. Among the 308 with favorable TB treatment outcomes, 68 
(22%) had documented cure, and 240 (78%) completed therapy (Table 1).  
 
Multivariable logistic regression was performed to identify factors independently associated with an 
unfavorable TB treatment outcome. In the model including all 386 HIV/TB co-infected children, neither 
mode of diagnosis (OR 1.77; 95%CI 0.86-3.65), IP regimen (OR 0.88; 95%CI 0.43-1.80), nor ART status 
(OR 0.71; 95%CI 0.38-1.31) were significantly associated with TB treatment outcome. Better nutritional 
status/higher WAZ was protective against unfavorable TB treatment outcomes (OR 0.35; 95% CI 0.67-
0.94). Children in the Asia-Pacific (OR 0.35; 95% CI 0.14-0.89) and Southern Africa (0.34; 95% CI 0.14-
0.84) IeDEA regions had significantly lower odds of having an unfavorable outcome compared with the 
Eastern Africa region. In the subgroup analysis restricted to children younger than five years, those with 
microbiological confirmation of TB had higher odds of unfavorable TB outcome (OR 3.8; 95%CI 1.12-
12.94) (Table 3). When previously treated TB cases were excluded (n=8), results were similar (data not 
shown).   
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Among HIV/TB co-infected children who were ART naïve at the time of TB diagnosis and were alive and 
retained in care eight weeks later, ART initiation within eight weeks of TB diagnosis was higher for those 
with favorable TB outcomes (64%) compared to those with unfavorable TB outcomes (40%) (p=0.04) 
(Figure 2).  
 
 
DISCUSSION  
 
In this large multinational study of HIV/TB co-infected children, many were not diagnosed or treated per 
WHO guidelines. Eighty percent of diagnoses were clinical (without microbiologic confirmation), and 
NAAT use was infrequent. Nearly one-quarter of patients did not receive a four-drug IP regimen 
including ethambutol. Only half of ART naïve children were started on ART within eight weeks of TB 
diagnosis, and 13% of patients were not started on ART during the study period. Overall, 20% of HIV/TB 
co-infected children in this cohort had unfavorable TB treatment outcomes. Those who initiated ART 
earlier were more likely to have favorable TB treatment outcomes. Among those younger than five years 
of age, those with microbiologic confirmation of TB had higher odds of unfavorable TB treatment 
outcomes.  
 
While at first the finding that microbiologic confirmation of TB is associated with unfavorable TB 
outcomes among the youngest patients seems counterintuitive, this might be explained in several ways. 
First, there is likely over-diagnosis of TB among clinical cases (false-positives) and therefore better 
outcomes in this group. Second, more extensive disease, and therefore higher bacterial burden, could 
both facilitate microbiologic confirmation of TB and be associated with poorer outcomes. Third, awaiting 
culture results in the absence of NAAT confirmation may have delayed TB treatment and possibly ART 
initiation, and therefore resulted in a greater likelihood of unfavorable TB treatment outcomes.  
 
This study highlights an urgent need to improve diagnosis of TB among HIV/TB co-infected children in 
LMIC. Only 20% of children diagnosed with TB had microbiologic confirmation of disease, and only 18% 
of cases were tested with NAAT. Similarly, in 2012 we conducted a site-level survey of pediatric ART 
programs in six IeDEA regions and found that NAAT was available at about one-third of sites; and, 
among 146 children who developed TB, AFB smear was utilized for 52%, mycobacterial culture for 17%, 
and NAAT for only 8%.
19
 Among the many impediments to TB diagnosis in children is obtaining 
diagnostic respiratory specimens. Performing early morning gastric aspirates can improve diagnostic 
yield, but requires hospitalization, which is often not practical in LMIC. Capacity to perform sputum 
induction in the outpatient setting is growing, and can improve diagnostic yield in children unable to 
spontaneously expectorate sputum. Even when a good specimen is obtained, access to diagnostics may 
be limited in LMIC. Furthermore, the yield of diagnostics is low due to paucibacillary disease in children, 
particularly those with compromised immune systems.
12,18
 Strategies to improve pediatric TB diagnosis 
should be multifaceted, and might include: improving the accuracy of clinical diagnosis, enhancing the 
implementation and utilization of current and emerging NAAT platforms,
1
 and developing non-sputum 
based diagnostics.
33-35
 
 
WHO makes a “strong recommendation” that a four-drug IP regimen including ethambutol be used for 
children from settings where the HIV prevalence is greater than 1% or there is high prevalence (as 
defined by national treatment programs) of INH resistance, in order to minimize the risk of developing 
or transmitting drug-resistant TB.6,14 IP regimen did not have an impact on TB treatment outcomes in 
this cohort, despite about one-quarter of HIV/TB co-infected children not receiving ethambutol.  
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This study adds to the literature that supports early ART as an important part of TB treatment for HIV/TB 
co-infected persons,
36-39
 and as such highlights the concerning observation that only half of ART naïve 
patients in this cohort were started on ART within eight weeks of TB diagnosis and that 13% of patients 
were not started on ART during the study period. Other studies have also reported delays in ART 
initiation,
40
 and there is some evidence that failing to implement WHO guidelines is associated with 
substantial mortality.
41
 Further implementation research aimed at improving access to ART for HIV/TB 
co-infected children is essential.   
 
Regional differences in outcomes are also important to acknowledge. Patients in the Asia-Pacific and 
Southern Africa regions were less likely to have unfavorable TB treatment outcomes. These two regions 
also had the highest utilization of sputum induction, gastric aspirates, and NAAT. There were especially 
high LTFU rates in the Western Africa region, resulting in this region having the highest proportion of 
unfavorable TB treatment outcomes. It is possible that those who were LTFU may have had different 
characteristics than those who were classified as having unfavorable outcomes for some other reason. 
However, due to the relatively small number of unfavorable outcomes, it would be difficult to draw 
conclusions from sensitivity analyses disaggregating these unfavorable outcomes. Furthermore, other 
reports have demonstrated significant mortality among those who are LTFU from HIV care and 
treatment programs.
42-44
 Regardless, improving access to diagnostics and interventions aimed at 
reducing attrition from care could lead to improved outcomes. Additionally, better understanding of the 
factors that contribute to heterogeneity between sites and regions could result in improved 
implementation of diagnostic and treatment services.   
 
We were unable to fully assess the appropriateness of ART regimens and modifications to ART regimens 
in the context of TB treatment, due to the absence of data on weight-based dosing of ART and ATT. The 
antiretrovirals nevirapine (a NNRTI) and lopinavir/ritonavir (a boosted PI) significantly interact with the 
anti-TB medication rifampin and require dose adjustment or changing to an alternative antiretroviral 
regimen. For those who were treated with nevirapine or lopinavir/ritonavir, it would be important to 
know whether ART dose adjustments were made. A second limitation was incomplete data for CD4 
count/percentage, HIV viral load (75% missing), WAZ, and ART status. We accounted for incomplete 
data in our logistic regression models using multiple imputation.  
 
In conclusion, in this large multinational population of HIV/TB co-infected children, many were not 
managed per WHO guidelines. Children with favorable TB outcomes initiated ART sooner than children 
with unfavorable outcomes. These findings highlight the importance of early ART for children with 
HIV/TB co-infection, and reinforce the need for implementation research to improve pediatric TB 
management. 
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Figure 1: HIV/TB co-infected children included in the study, by IeDEA Network region and country. 
Numbers in parentheses indicate the number of children contributed by each country.  
 
Figure 2: Cumulative incidence of antiretroviral therapy initiation within eight weeks after TB diagnosis, 
among HIV/TB co-infected children who were previously ART naïve and who were alive and retained in 
care at eight weeks after TB diagnosis. 
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Table 1: Characteristics of HIV/TB co-infected children at time of TB diagnosis, stratified by TB treatment outcome, 2012-2014.  
 Favorable Outcome Unfavorable Outcome Combined 
 
Completed  
ATT (n=240) 
Cure 
(n=68) 
All Favorable  
(n=308) 
 
Death 
(n=30) 
Treatment  
Failure (n=1) 
LTFU 
(n=33) 
Unknown 
(n=14) 
All 
Unfavorable 
(n=78) 
(N=386) 
Age, median (IQR)  6 (2.1 - 9.8)  5.5 (2.7 - 9.4)  5.9 (2.4 - 9.6) 5.4 (2 - 9.8)  
10.2 (10.2 - 
10.2)  
3.6 (1 - 6.7)  8.1 (6.6 - 9.6)  5.5 (1.1 - 8.8) 5.7 (2.0 - 9.5) 
Age group, n (%)          
     0 – 4.9 years 100 (42%)  29 (43%)  129 (42%)  13 (43%)  0 (0%)  19 (58%)  3 (21%)  35 (45%)  164 (43%)  
     5 – 9.9 years 80 (33%)  25 (37%)  105 (34%)  9 (30%)  0 (0%)  10 (30%)  8 (57%)  27 (35%)  132 (34%)  
     10 – 15 years 60 (25%)  14 (21%)  74 (24%)  8 (27%)  1 (100%)  4 (12%)  3 (21%)  16 (21%)  90 (23%)  
Female, n (%)  121 (50%)  28 (41%)  149 (48%) 13 (43%)  1 (100%)  11 (33%)  7 (50%)  32 (41%) 181 (47%) 
WAZ, median (IQR)  
-2.33  
(-3.57 - -1.11)  
-2.91  
(-3.76 - -1.98)  
-2.45  
(-3.66 - -1.36) 
-4.36  
(-5.13 - -2.45)  
-4.25  
(-4.25 - -4.25)  
-2.64  
(-3.54 - -1.81)  
-3.75  
(-4.89 - -2.94)  
-3.26  
(-4.84 - -2.18) 
-2.69  
(-3.82 - -1.48) 
        Missing, n (%)  45 (19%)  6 (9%)  51 (17%) 5 (17%)  0 (0%)  7 (21%)  4 (29%)  16 (21%) 67 (17%) 
CD4 count*, median 
(IQR) 
262 (70 - 665)  117 (16 - 531)  229 (54-638) 145 (63 - 324)  92 (92 - 92)  
670 (367 - 
890)  
85 (20 - 268)  267 (81-670) 247 (60-668) 
        Missing, n (%)  55 (23%)  2 (3%)  57 (19%) 8 (27%)  0 (0%)  10 (30%)  3 (21%)  21 (27%) 78 (20%) 
CD4 %†, median (IQR)  12 (4 - 22)  5 (1 - 18)  10 (3 - 22) 7 (2 - 13)  11 (11 - 11)  17 (10 - 22)  7 (4 - 10)  10 (5 - 17) 10 (3 - 20) 
        Missing, n (%)  75 (31%)  7 (10%)  82 (27%) 8 (27%)  0 (0%)  11 (33%)  3 (21%)  22 (28%) 104 (27%) 
IeDEA region, n (%)           
        Asia-Pacific  17 (7%)  53 (78%)  70 (23%)  13 (43%)  0 (0%)  1 (3%)  0 (0%)  14 (18%)  84 (21%) 
        Central Africa  52 (22%)  1 (1%)  53 (17%)  3 (10%)  0 (0%)  4 (12%)  0 (0%)  7 (9%)  60 (15%) 
        Eastern Africa  60 (25%)  9 (13%)  69 (22%)  10 (33%)  0 (0%)  3 (9%)  12 (86%)  25 (32%)  94 (26%) 
        Southern Africa  76 (32%)  1 (1%)  77 (25%)  1 (3%)  0 (0%)  8 (24%)  2 (14%)  11 (14%)  88 (23%) 
        Western Africa  35 (15%)  4 (6%)  39 (13%)  3 (10%)  1 (100%)  17 (52%)  0 (0%)  21 (27%)  60 (16%) 
ATT = anti-TB therapy; IQR = interquartile range; LTFU = loss to follow-up; WAZ = weight-for-age Z-score 
* Median CD4 count among those ≥ 5 years was 144 cells/mm
3
 (IQR 28-403 cells/mm
3
; 14% missing data).  
† Median CD4 percentage among those < 5 years was 16% (IQR 8-23%; 34% missing data). 
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Table 2: Summary of TB diagnostics, sites of disease, treatment, and ART status for HIV/TB co-infected children, stratified by TB treatment 
outcome category. 
 
Favorable outcome 
(n=308) 
Unfavorable outcome 
(n=78) 
Combined 
(N=386) 
Test Result, n (%)     
        Microbiologic diagnosis* 
     AFB smear positive 
61 (20%) 
25 (8%) 
18 (23%) 
11 (14%) 
79 (20%) 
36 (9%)  
AFB culture positive 28 (9%) 5 (6%) 33 (9%)  
NAAT positive 37 (12%) 11 (15%) 48 (12%)  
        Clinical diagnosis  247 (80%) 60 (77%) 307 (80%) 
     Negative test result(s) 127 (41%) 28 (36%) 155 (40%)  
     No test performed 120 (39%) 32 (41%) 152 (39%)  
    
Site of disease, n (%)     
        Pulmonary  229 (74%) 58 (74%) 287 (74%) 
        Extra-pulmonary*  60 (19%) 13 (17%) 73 (19%) 
     Abdominal 30 (10%) 5 (6%) 35 (9%)  
     CNS/Meningeal 3 (1%) 1 (1%) 4 (1%)  
     Lymphatic 16 (5%) 9 (12%) 25 (7%)  
     Miliary 4 (1%) 2 (3%) 6 (2%)  
     Osteoarticular 2 (1%) 0 (0%) 2 (<1%)  
     Pericardial 1 (<1%) 1 (1%) 2 (<1%)  
     Pleural 4 (1%) 3 (4%) 7 (2%)  
     Unknown 11 (4%) 1 (1%) 12 (3%)  
        Both  18 (6%) 7 (9%) 25 (6%) 
    
Intensive phase regimen, n (%)†    
        3-drug HRZ 62 (20%) 22 (28%) 84 (22%) 
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        4-drug HRZE 246 (80%) 56 (72%) 302 (78%) 
    
ART status, n (%)    
        ART prior to TB diagnosis 101 (33%) 18 (23%) 119 (31%) 
        ART ≤8 weeks after TB diagnosis 109 (34%) 15 (19%)  124 (32%) 
        ART >8 weeks after TB diagnosis 45 (15%) 8 (10%) 53 (14%) 
        No ART 25 (8%) 25 (32%) 50 (13%) 
        Missing 28 (9%) 12 (15%) 40 (10%) 
* More than one can apply, thus numbers do not add up to 100% 
† A 3-drug regimen includes isoniazid (H), rifampin (R), and pyrazinamide (Z). A 4-drug regimen includes HRZ and ethambutol (E).   
AFB = acid fast bacilli; NAAT = nucleic acid amplification test; ART = antiretroviral therapy 
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Table 3: Logistic regression models to identify factors associated with an unfavorable TB treatment outcome. 
 All Pediatric Patients Children under 5 Children aged 5-15 
 Odds Ratio (95% CI)1 Odds Ratio (95% CI)2 Odds Ratio (95% CI)3  
Microbiologic diagnosis (vs. Clinical diagnosis )  1.77 (0.86, 3.65) 3.80 (1.12, 12.90) 1.45 (0.53, 4.00)  
3-drug HRZ regimen (vs. 4-drug HRZE)* 0.88 (0.43, 1.80) 0.84 (0.23, 2.99) 0.91 (0.33, 2.50)  
On ART at TB diagnosis (vs. not on ART) 0.71 (0.38, 1.31) 1.04 (0.40, 2.67) 0.48 (0.21, 1.14)  
Age (per 1 year)  0.96 (0.89, 1.03) 0.83 (0.62, 1.13) 1.01 (0.88, 1.15)  
Weight-for-age Z-score (per 1 standard deviation) 0.80 (0.67, 0.94) 0.80 (0.63, 1.02) 0.78 (0.61, 1.01)  
CD4 count (per 10 cells)  1.00 (1.00, 1.01) omiKed† 1.00 (0.99, 1.02)  
CD4 percentage (per 1 unit) omiKed† 1.00 (0.96, 1.05) omiKed† 
Female (vs. Male)  0.77 (0.45, 1.32) 0.93 (0.41, 2.11) 0.64 (0.30, 1.40)  
Region     
        Eastern Africa (reference)  1 1 1  
        Asia-Pacific  0.35 (0.14, 0.89) 0.28 (0.05, 1.43) 0.41 (0.12, 1.40)  
        Central Africa  0.47 (0.18, 1.23) 0.88 (0.22, 3.52) 0.23 (0.04, 1.21)  
        Southern Africa  0.34 (0.14, 0.84) 0.91 (0.23, 3.59) 0.08 (0.02, 0.45)  
        Western Africa  1.22 (0.57, 2.62) 2.81 (0.69, 11.53) 0.78 (0.31, 1.99)  
1
There are 386 patients included in this model; 78 had an unfavorable outcome.  
2
There are 164 patients <5 years old included in this model; 35 had an unfavorable outcome. 
3
There are 222 patients 5-15 years old included in this model; 43 had an unfavorable outcome.  
* A 3-drug regimen includes isoniazid (H), rifampin (R), and pyrazinamide (Z). A 4-drug regimen includes HRZ and ethambutol (E).   
† CD4 count and CD4 percentage are correlated, so to save degrees of freedom only one or the other was used in each regression model. 
Consistent with their clinical application, CD4 percentage was used in the model for those <5 years old, while CD4 count was used for the models 
including children 5-15 years old.  
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Western Africa: 
• Côte d’Ivoire (32) 
• Ghana (30) 
Southern Africa: 
• South Africa (91) 
Central Africa: 
• Burundi (1) 
• République 
Démocratique 
du Congo (54) 
• Rwanda (6)  
Eastern Africa: 
• Kenya (61) 
• Tanzania (21) 
• Uganda (20)  Asia-Pacific:  
• Indonesia (21) 
• Vietnam (63)  
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